ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose We evaluated the clinical utility of excision repair cross-complementation group 1 (ERCC1) expression as a predictive biomarker for platinum-based chemotherapy in advanced nonsmall cell lung cancer (NSCLC). Materials and Methods Eligible patients were randomly assigned to the GP (gemcitabine 1,250 mg/m2 on days 1 and 8, and cisplatin 75 mg/m2 on day 1 every 3 weeks) or IP (irinotecan 65 mg/m2 and cisplatin 30 mg/m2 on days 1 and 8 every 3 weeks) arm. The primary goal of this study was to compare the response rate (RR) of the GP and IP arms according to the ERCC1 expression level. Results A total of 279 patients were randomly assigned to the GP (n=139) and IP (n=140) arms, among which 63% were ERCC1-positive and 268 patients were assessable for the RR. The GP and IP arms did not differ significantly with respect to the RR (29.8% vs. 27.0%, respectively; p=0.082), median progression-free survival (PFS; 4.5 months vs. 3.9 months, respectively; p=0.117), and overall survival (OS; 16.5 months vs. 16.7 months, respectively; p=0.313). When comparing the efficacy between the ERCC1-positive and ERCC1-negative groups, there was no significant difference in the RR (GP, 28.2% vs. 32.6%, respectively, p=0.509; IP, 30.2% vs. 21.6%, respectively, p=0.536), median PFS (GP, 4.6 months vs. 5.0 months, respectively, p=0.506; IP, 3.9 months vs. 3.7 months, respectively, p=0.748), or median OS (GP, 18.6 months vs. 11.9 months, respectively, p=0.070; IP, 17.5 months vs. 14.0 months, respectively, p=0.821). Conclusion Immunohistochemical analysis of the ERCC1 expression level did not differentiate the efficacy of platinum-based chemotherapy in advanced NSCLC.
Abstract
Purpose We evaluated the clinical utility of excision repair cross-complementation group 1 (ERCC1) expression as a predictive biomarker for platinum-based chemotherapy in advanced nonsmall cell lung cancer (NSCLC). Materials and Methods Eligible patients were randomly assigned to the GP (gemcitabine 1,250 mg/m2 on days 1 and 8, and cisplatin 75 mg/m2 on day 1 every 3 weeks) or IP (irinotecan 65 mg/m2 and cisplatin 30 mg/m2 on days 1 and 8 every 3 weeks) arm. The primary goal of this study was to compare the response rate (RR) of the GP and IP arms according to the ERCC1 expression level. Results A total of 279 patients were randomly assigned to the GP (n=139) and IP (n=140) arms, among which 63% were ERCC1-positive and 268 patients were assessable for the RR. The GP and IP arms did not differ significantly with respect to the RR (29.8% vs. 27.0%, respectively; p=0.082), median progression-free survival (PFS; 4.5 months vs. 3.9 months, respectively; p=0.117), and overall survival (OS; 16.5 months vs. 16.7 months, respectively; p=0.313). When comparing the efficacy between the ERCC1-positive and ERCC1-negative groups, there was no significant difference in the RR (GP, 28.2% vs. 32.6%, respectively, p=0.509; IP, 30.2% vs. 21.6%, respectively, p=0.536), median PFS (GP, 4.6 months vs. 5.0 months, respectively, p=0.506; IP, 3.9 months vs. 3.7 months, respectively, p=0.748), or median OS (GP, 18.6 months vs. 11.9 months, respectively, p=0.070; IP, 17.5 months vs. 14.0 months, respectively, p=0.821). Conclusion Immunohistochemical analysis of the ERCC1 expression level did not differentiate the efficacy of platinum-based chemotherapy in advanced NSCLC.
참고문헌 (25)
- Cufer T, "Systemic therapy of advanced non-small cell lung cancer : major-developments of the last 5-years", Eur J Cancer, 49, pp.1216~1225 (2013)
- Cooper WA, "What's new in non-small cell lung cancer for pathologists : the importance of accurate subtyping, EGFR mutations and ALK rearrangements", Pathology, 43, pp.103~115 (2011)
- Schiller JH, "Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer", N Engl J Med, 346, pp.92~98 (2002)
- Ohe Y, "Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer : Four-Arm Cooperative Study in Japan", Ann Oncol, 18, pp.317~323 (2007)
- Rose MC, "Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer", Genomics Proteomics Bioinformatics, 12, pp.198~209 (2014)
- Bergstralh DT, "Interstrand crosslink repair: can XPF-ERCC1 be let off the hook", Trends Genet, 24, pp.70~76 (2008)
- Zheng Z, "DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer", N Engl J Med, 356, pp.800~808 (2007)
- Lord RV, "Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer", Clin Cancer Res, 8, pp.2286~2291 (2002)
- Chen S, "The platinum-based treatments for advanced non-small cell lung cancer, is low", negative ERCC1 expression better than high, Lung Cancer, pp.2010, 70[DOI]
- Vilmar AC, "ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial", Ann Oncol, 21, pp.1817~1824 (2010)
- Olaussen KA, "DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy", N Engl J Med, 355, pp.983~991 (2006)
- Cobo M, "Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression : a phase III trial in non-small-cell lung cancer", J Clin Oncol, 25, pp.2747~2754 (2007)
- Reynolds C, "Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer", J Clin Oncol, 27, pp.5808~5815 (2009)
- Vallbohmer D, "Molecular determinants of irinotecan efficacy", Int J Cancer, 119, pp.2435~2442 (2006)
- Trotti A, "CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment", Semin Radiat Oncol, 13, pp.176~181 (2003)
- Sohaib SA, "CT assessment of tumour response to treatment : comparison of linear, cross-sectional and volumetric measures of tumour size", Br J Radiol, 73, pp.1178~1184 (2000)
- Han JY, "Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)therapy in never-smokers with lung adenocarcinoma", Lung Cancer, 85, pp.161~167 (2014)
- Kim H, "Detection of ALK gene rearrangement in non-small cell lung cancer : a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression", J Thorac Oncol, 6, pp.1359~1366 (2011)
- Bepler G, "Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine", carboplatin in advanced non-small-cell lung cancer, 2013, pp.31, 2404~2412
- Friboulet L, "ERCC1 isoform expression and DNA repair in non-small-cell lung cancer", N Engl J Med, 368, pp.1101~1110 (2013)
- Wislez M, "Customized adjuvant phase II trial in patients with nonsmall-cell lung cancer : IFCT-0801 TASTE", J Clin Oncol, 32, pp.1256~1261 (2014)
- Schneider JG, "Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancer", Oncologist, 19, pp.459~465 (2014)
- Tantraworasin A, "The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer : tumor recurrence and overall survival", Cancer Manag Res, 5, pp.327~336 (2013)
- Tiseo M, "ERCC1", BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin, 2013, pp.108, 1695~1703
- Yu D, "Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients", Tumour Biol, 33, pp.877~884 (2012)